Psoriatic Arthritis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

1 Psoriatic Arthritis: Executive Summary

1.1 Sunsetting older therapies, biosimilars, and generics dampen PsA market growth

1.2 Strategic positioning established by the PsO market

1.3 Lack of innovation provides market opportunity

1.4 Johnson & Johnson leads PsA pipeline assets with icotrokinra

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.2 Etiology

3.3 Genetic factors

3.4 Environmental and lifestyle factors

3.5 Pathophysiology

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Diagnosed incident cases of PsA

4.4.4 Diagnosed prevalent cases of PsA

4.4.5 Diagnosed prevalent cases of PsA by type

4.4.6 Diagnosed prevalent cases of PsA by severity

4.4.7 Diagnosed prevalent cases of PsA with comorbidity

4.4.8 Diagnosed prevalent cases of PsA with psoriasis

4.5 Epidemiological forecast for PsA (2023–33)

4.5.1 Diagnosed incident cases of PsA

4.5.2 Sex-specific diagnosed incident cases of PsA

4.5.3 Age-specific diagnosed incident cases of PsA

4.5.4 Diagnosed prevalent cases of PsA

4.5.5 Sex-specific diagnosed prevalent cases of PsA

4.5.6 Age-specific diagnosed prevalent cases of PsA

4.5.7 Diagnosed prevalent cases by type

4.5.8 Diagnosed prevalent cases by severity

4.5.9 Diagnosed prevalent cases by comorbidity

4.5.10 Diagnosed prevalent cases of PsA with psoriasis

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 Key opinion leader insights on disease management

6 Current Treatment Options

6.1 Overview

6.1.1 Tumor necrosis factor inhibitors

6.1.2 IL-17 Inhibitors

6.1.3 IL-23 Inhibitors

6.1.4 Janus kinase inhibitors

6.1.5 Other targeted synthetic disease modifying anti-rheumatic drugs

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Highly efficacious therapies

7.3 Biomarkers

7.4 Treating PsA and its comorbidities

7.5 Identifying the subclinical state of PsA

8 R&D Strategies

8.1 Overview

8.1.1 Market significant shift towards small molecules

8.1.2 Development with an eye on market positioning

8.2 Clinical trials design

8.2.1 Active comparator trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

9.2.1 JNJ-4804

9.2.2 Ilumya

9.2.3 Icotrokinra

9.2.4 Sonelokimab

9.2.5 Zasocitinib

9.2.6 Sotyktu

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Biologic therapies

10.2.2 Small molecule therapies

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – key opinion leaders interviewed for this report

13.4.1 Key opinion leaders

13.4.2 Payers

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

13.7 Contact Us

Table 1: PsA: key metrics in the 7MM

Table 2: Risk factors and comorbidities for PsA

Table 3: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023

Table 4: Treatment Guidelines for PsA

Table 5: Top completed deals in PsA market by value, 2018–23

Table 6: Disease PsA market – global drivers and barriers, 2023–33

Table 7: Key events impacting sales for PsA in the US, 2023–33

Table 8: Disease PsA market – drivers and barriers in the US, 2023–2033

Table 9: Key events impacting sales for PsA in the 5EU, 2023–33

Table 10: PsA market – drivers and barriers in the 5EU, 2023–33

Table 11: Key events impacting sales for PsA in Japan, 2023–33

Table 12: PsA market – drivers and barriers in Japan, 2023–33

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for PsA in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in PsA during the forecast period

Figure 3: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara

Figure 4: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq

Figure 5: 7MM, diagnosed incidence of PsA (cases per 100,000 population), men and women, ages ≥18 years, 2023

Figure 6: 7MM, diagnosed prevalence of PsA (%), men and women, ages ≥18 years, 2023

Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PsA

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PsA

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PsA by type

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PsA with comorbidity

Figure 11: 7MM, diagnosed incident cases of PsA (N), men and women, ages ≥18 years, 2023

Figure 12: 7MM, diagnosed incident cases of PsA by sex (N), ages ≥18 years, 2023

Figure 13: 7MM, diagnosed incident cases of PsA by age (N), men and women, 2023

Figure 14: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages ≥18 years, 2023

Figure 15: 7MM, diagnosed prevalent cases of PsA by sex (N), ages ≥18 years, 2023

Figure 16: 7MM, diagnosed prevalent cases of PsA by age (N), men and women, 2023

Figure 17: 7MM, diagnosed prevalent cases by type (N), men and women, ages ≥18 years, 2023

Figure 18: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023

Figure 19: 7MM, diagnosed prevalent cases of PsA with PsO (N), men and women, ages ≥18 years

Figure 20: Unmet needs and opportunities in PsA

Figure 21: Overview of the development pipeline in PsA

Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsA in the 7MM during the forecast period

Figure 23: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara

Figure 24: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq

Figure 25: Analysis of the company portfolio gap in PsA during the forecast period

Figure 26: Global (7MM) sales forecast by country for PsA in 2023 and 2033

Figure 27: Sales forecast by class for PsA in the US in 2023 and 2033

Figure 28: Sales forecast by class for PsA in the 5EU in 2023 and 2033

Figure 29: Sales forecast by class for PsA in Japan in 2023 and 2033